pharmaphorum

JUNE 1, 2022

For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. ASCO ’22 provides the perfect backdrop to dive into ways we can collectively drive patient-centric oncology research and development (R&D). Equitable care for all. About the authors.

Hospitals 59

Hospitals 59

pharmaphorum

AUGUST 15, 2022

At this year’s ASCO congress, the Trop2-targeting antibody-drug conjugate (ADC) was found to improve progression-free survival significantly in in patients with hormone receptor-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment.

Labelling 90

Labelling FDA 90

pharmaphorum

APRIL 14, 2021

The two organisations began their collaboration shortly after Amgen created a stir at the American Society of Clinical Oncology (ASCO) conference with the first clinical evidence of an effect on solid tumours from a KRAS-targeting drug. Novartis signed a deal to evaluate Mirati’s drug soon after ASCO 2019.

FDA 52

FDA 52

pharmaphorum

JULY 7, 2022

ASCO 2022: Checkpoint inhibitors, Enhertu in spotlight. pharmaphorum editor in chief Jonah Comstock rounds up key developments from the American Society of Clinical Oncology’s first in-person conference since COVID began. Read Deep Dive: Oncology in full.

Vaccines 52

Vaccines Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

SEPTEMBER 7, 2020

Approval sets up a rivalry with Eli Lilly’s RET inhibitor Retevmo (selpercatinib), and the verdict from experts at this year’s American Society of Clinical Oncology (ASCO) was that the two drugs are interchangeable, based on available trial data.

FDA 52

FDA Chemotherapy 52

pharmaphorum

MAY 30, 2022

The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers came together in person for the first time since the start of the pandemic at the ESMO Breast Cancer congress.

Chemotherapy 116

Chemotherapy Immunization 116

pharmaphorum

JULY 25, 2022

Enhertu also has a six-month priority review from the US regulator, so a decision on its new use in metastatic, HER2-low breast cancer should be made within six months.

FDA 59

FDA Chemotherapy 59

pharmaphorum

JUNE 30, 2021

Read on for a look at highlights from ASCO, new approaches to clinical trials, and the transformative impact of digital in oncology. ASCO highlights: the next generation of cancer therapy . We roundup the biggest stories from this year’s conference, giving us a glimpse into the exciting future of oncology.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Communication 52

pharmaphorum

DECEMBER 23, 2020

The American Society of Clinical Oncology (ASCO) annual conference was one of the highlights of the year in cancer research and the fact it was held virtually did not distract from some stunning clinical lung cancer trial results presented by AstraZeneca.

FDA 96

FDA Chemotherapy Compounding Vaccines 96

pharmaphorum

MAY 7, 2021

This post-surgical treatment is backed by findings of the phase 3 ADAURA trial, which was the highlight of last year’s American Society of Clinical Oncology (ASCO) conference.

Labelling 52

Labelling FDA 52

pharmaphorum

OCTOBER 8, 2021

On a conference, called chief executive David Chang said the biotech was surprised by the FDA’s decision to impose a clinical hold, as this is the only case of chromosomal abnormality out of more than 100 patients treated with its CAR-T therapies to date.

FDA 52

FDA 52

pharmaphorum

JUNE 7, 2021

Results of the phase 1/2 ZUMA-3 trial of Tecartus (brexucabtagene autoleucel) reported at the ongoing ASCO conference revealed a 71% complete response rate with the CAR-T in heavily pre-treated adult patients with B-cell precursor ALL. The median response duration was 12.8

FDA 105

FDA Labelling Immunization 105

pharmaphorum

OCTOBER 20, 2020

Results from the phase 3 ADAURA trial were the talk of this year’s American Society of Clinical Oncology (ASCO) conference in summer and the regulator has granted a Priority Review for a label extension based on the results.

FDA 64

FDA Labelling 64

pharmaphorum

OCTOBER 4, 2021

Under the terms of the deal, Janssen will fund 80% of the development of plamotamab, including a new subcutaneous formulation of the drug which should start clinical testing this year, said Xencor on a conference call. The drug was previously licensed to Novartis, but the Swiss group ducked out of that arrangement in 2019.

Chemotherapy 52

Chemotherapy Immunization FDA 52

pharmaphorum

MAY 21, 2021

Data announced ahead of this year’s American Society of Clinical Oncology (ASCO) conference suggest that Gilead and CAR-T rivals Bristol-Myers Squibb and Novartis better watch their backs as Allogene announced plans for a pivotal study this year.

53

53

Pharma Marketing Network

JANUARY 19, 2022

If a brand talks at conferences are doctors going to hear it? Talkie” ads on ililli at ASCO got an 18% CTR. Thousands of ophthalmologists heard talks about the AAO. Those talks played for nearly 70 hours. That’s a lot of media. A lot of talk. The kind of media that a brand would like to be part of. They had 300×600 banner ad.

97

97

pharmaphorum

FEBRUARY 15, 2021

To recap, Padcev (enfortumab vedotin) was quickly okayed by the FDA in December 2019 in advanced urothelial cancer on the basis of phase 2 response data that made it a rising star at that year’s American Society of Clinical Oncology (ASCO) conference.

Chemotherapy 69

Chemotherapy FDA 69

pharmaphorum

MAY 20, 2021

LAG-3 drugs from arch-rivals Bristol-Myers Squibb and Merck & Co look set to become talking points at this year’s ASCO conference after trial results showed their potential as next-generation cancer immunotherapies. In those receiving the combination, the median progression-free survival (PFS) was significantly longer at 10.12

Immunization 52

Immunization FDA 52

Pharmaceutical Technology

JUNE 6, 2023

Following the publication of clinical data from its Phase I study of the inhibitor at the American Society of Clinical Oncology (ASCO) conference, Ellipses was motivated to accelerate clinical development due to what it believes are “very encouraging” results. The ASCO Annual Meeting is being held 2–6 June in Chicago.

Communication 52

Communication 52

Pharmaceutical Technology

JUNE 5, 2023

In results presented at the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting , Summit reported an overall response rate (ORR) of 67% in NSCLC patients with squamous histology treated with its lead drug ivonescimab plus chemotherapy. The ASCO conference is being held 2–6 June in Chicago.

Chemotherapy 52

Chemotherapy Communication 52